View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase 2 Trial

In Clinical Trials by Barbara Jacoby

Source: Translational Research in Oncology From: globenewswire.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of the first patient in a Phase 2 randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche. GDC-9545 is a selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity …

View Post

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer

In Clinical Trials by Barbara Jacoby

Source: Linnaeus Therapeutics, Inc. From: PR Newswire Company Commences Phase 2 Study at Multiple Academic Sites in United States Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, …

View Post

Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Lisa Astor From: targetedonc.com Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial. Patients with endocrine-sensitive hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, treated with Frontline …

View Post

Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase 2 Trial

In Clinical Trials by Barbara Jacoby

Source: Translational Research in Oncology From: globenewswire.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of the first patient in a Phase 2 randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche. GDC-9545 is a selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity …

View Post

Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com The Canadian Cancer Trials Group (CCTG) today announced the commencement of a phase 2 study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 (PLK4) in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer (TNBC). “Immunotherapy in combination with chemotherapy has shown promise in this disease; however, non-chemotherapy …

View Post

Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions

In Clinical Trials by Barbara Jacoby

From: PR Newswire Partnership explores innovative models for real-time identification, patient referral and enrollment of patients with solid tumors with a rare gene fusion Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it has entered into a strategic partnership with Elevation Oncology to enhance patient enrollment practices for …

View Post

Investigational vaccine and immune therapy work well together to fight breast cancer

In In The News by Barbara Jacoby

Source: Duke University Medical Center From: news-medical.net A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research. The vaccine …

View Post

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

From: targetedonc.com Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer. Ian E. Krop, MD, PhD, an associate professor of medicine with Harvard Medical School; associate chief, Division of Breast Oncology with Susan F. Smith …

View Post

Liquid biopsy may predict early-stage TNBC recurrence

In Clinical Trials by Barbara Jacoby

By: Shreeya Nanda From: medwirenews.com The presence of circulating tumor (ct)DNA and circulating tumor cells (CTCs) in postsurgical samples is associated with relapse and poor outcomes in early-stage triple-negative breast cancer (TNBC) patients with an incomplete pathologic response to neoadjuvant chemotherapy, research suggests. Distant disease-free survival (DDFS), DFS, and overall survival (OS) were significantly worse for patients with versus without …